Lilia L Bi

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib
    Lilia L Bi
    Center for Biologics Evaluation and Research, FDA, Rockville, Maryland, USA
    BMC Med Genet 8:41. 2007
  2. ncbi Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome
    V Koneti Rao
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Hematol 82:1049-55. 2007

Collaborators

Detail Information

Publications2

  1. ncbi Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib
    Lilia L Bi
    Center for Biologics Evaluation and Research, FDA, Rockville, Maryland, USA
    BMC Med Genet 8:41. 2007
    ....
  2. ncbi Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome
    V Koneti Rao
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Hematol 82:1049-55. 2007
    ..We conclude that these drugs do not warrant further use empirically or as part of clinical trials in ALPS Type Ia as a lympholytic agent...